{
    "nct_id": "NCT00261573",
    "title": "The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia",
    "status": "COMPLETED",
    "last_update_time": "2011-05-17",
    "description_brief": "The purpose of this study is to evaluate the safety and efficacy of galantamine (a drug for treating dementia) compared to placebo in the treatment of patients with dementia related to cerebrovascular disease (vascular dementia) or dementia related to Alzheimer's disease with cerebrovascular disease (\"mixed\" dementia).",
    "description_detailed": "This multicenter, double-blind, placebo-controlled study will evaluate the safety and effectiveness of galantamine in patients with dementia related to cerebrovascular disease or related to Alzheimer's disease with cerebrovascular disease (\"mixed\" dementia). All patients will initially receive placebo for a 1-month period and then will receive galantamine (starting at a low dose and gradually increasing over 5 weeks to 12 mg twice daily) or placebo for 6 months. The primary measures of effectiveness include the change from baseline to the end of treatment in the ADAS-cog/11 score (Alzheimer's Disease Assessment Scale: sum of 11 cognitive items) and the CIBIC-plus score (Clinician's Interview Based Impression of Change - Plus Caregiver Input). Additional measures of effectiveness include the change from baseline to the end of the treatment in the ADAS-cog/13 score (Alzheimer's Disease Assessment Scale: sum of 13 cognitive items), the Disability Assessment for Dementia (DAD) score, and the Neuropsychiatric Inventory (NPI)) score. Safety evaluations (incidence of adverse events, electrocardiograms (ECGs), physical examinations, laboratory tests) will be performed throughout the study. Patients who complete the double-blind portion of the study will have the opportunity to participate in a 6-month open-label extension study in which they will receive galantamine for an additional 6 months. Effectiveness will be assessed after 6 weeks, 3 months and 6 months of open-label treatment. Safety evaluations (incidence of adverse events, ECGs, physical examinations, laboratory tests) will be performed throughout the open-label portion of the study. The study hypothesis is that galantamine will be effective in the treatment of patients with vascular or mixed dementia and will be well tolerated. Double-blind: Galantamine 12 mg or placebo by mouth twice daily for 6 months, starting at a low dose and gradually increasing over 5 weeks to the final dose; Open-label: galantamine 12 mg by mouth twice daily, starting at a low dose and gradually increasing over 6 weeks to the final dose.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "galantamine (Razadyne / Reminyl)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests galantamine versus placebo in vascular and mixed dementia. Galantamine is a centrally acting reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator that increases acetylcholine to improve cholinergic neurotransmission; it is approved for symptomatic treatment of mild\u2013moderate Alzheimer\u2019s disease and is not considered disease-modifying. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search5\ue201",
        "Act: Key extracted details \u2014 drug: galantamine (small-molecule alkaloid, marketed as Razadyne/Reminyl); intervention intent: symptomatic cognitive improvement in dementia (vascular or mixed). Because galantamine is a small-molecule cholinesterase inhibitor that aims to improve cognition rather than directly target Alzheimer\u2019s pathology (amyloid or tau), it fits the 'cognitive enhancer' category. \ue200cite\ue202turn0search8\ue202turn0search5\ue201",
        "Reflect: The classification aligns with the trial title and description (safety and efficacy of galantamine for dementia symptoms). Although the population includes vascular and mixed dementia (where pathology may include cerebrovascular disease and/or Alzheimer pathology), the drug\u2019s mechanism and clinical role are symptomatic cognitive enhancement rather than disease modification \u2014 therefore 'cognitive enhancer' is the correct category. Note: safety signals and regulatory notes (e.g., FDA safety communications) have been associated with galantamine and should be considered in trial context. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Web search sources (summary): 1) DrugBank \u2014 galantamine mechanism, approval status, not disease\u2011modifying. \ue200cite\ue202turn0search0\ue201 2) FDA drug information / safety alert on Razadyne (galantamine) \u2014 regulatory safety communications. \ue200cite\ue202turn0search1\ue201 3) StatPearls (NCBI) \u2014 mechanism of action as cholinesterase inhibitor and clinical use. \ue200cite\ue202turn0search2\ue201 4) ALZFORUM therapeutic overview \u2014 galantamine listed as small molecule, cholinergic-targeting symptomatic therapy. \ue200cite\ue202turn0search5\ue201 5) Systematic review / clinical evidence on galantamine in vascular cognitive impairment \u2014 efficacy and adverse event considerations. \ue200cite\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests galantamine, a centrally acting acetylcholinesterase inhibitor that increases synaptic acetylcholine and also has reported allosteric effects on nicotinic acetylcholine receptors. This mechanism focuses on enhancing cholinergic neurotransmission (a neurotransmitter/receptor-based symptomatic approach) rather than modifying amyloid, tau, or other disease pathways. \ue200cite\ue202turn0search4\ue202turn0search0\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 drug: galantamine (Razadyne/Reminyl); mechanism: acetylcholinesterase inhibition with nicotinic receptor modulatory activity; clinical intent: symptomatic cognitive enhancement in vascular/mixed dementia (not disease\u2011modifying). Based on CADRO, the most specific fit is D) Neurotransmitter Receptors because the intervention directly targets cholinergic neurotransmission. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Reflect: This classification aligns with the trial title and the drug\u2019s known pharmacology and clinical role. Evidence of galantamine\u2019s symptomatic effects in vascular and mixed dementia comes from randomized trials and systematic reviews, supporting the view that the drug\u2019s primary action is on neurotransmission rather than on core AD pathologies. Safety/tolerability concerns have been noted in trial reports and reviews. Therefore D) Neurotransmitter Receptors is the appropriate CADRO category. \ue200cite\ue202turn0search7\ue202turn0search6\ue202turn0search5\ue201",
        "Web search results (sources used): 1) DrugBank summary and galantamine pharmacology (mechanism: AChE inhibitor; nicotinic modulation; not disease-modifying). \ue200cite\ue202turn0search4\ue201 2) DrugBank / J Neurosci and PNAS articles describing nicotinic receptor effects and AChE inhibition. \ue200cite\ue202turn0search0\ue202turn0search2\ue201 3) Lancet randomized trial reporting efficacy in patients with probable vascular dementia / mixed AD+cerebrovascular disease. \ue200cite\ue202turn0search7\ue201 4) Neurology (multinational RCT) showing cognitive benefit in vascular dementia. \ue200cite\ue202turn0search6\ue201 5) Cochrane review summarizing trials in vascular cognitive impairment (benefit on cognition but adverse GI events). \ue200cite\ue202turn0search5\ue201"
    ]
}